ID
34394
Description
A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms; ODM derived from: https://clinicaltrials.gov/show/NCT01309789
Link
https://clinicaltrials.gov/show/NCT01309789
Keywords
Versions (1)
- 1/17/19 1/17/19 -
Copyright Holder
see on clinicaltrials.gov
Uploaded on
January 17, 2019
DOI
To request one please log in.
License
Creative Commons BY 4.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Eligibility Lymphoma, Large-Cell, Anaplastic NCT01309789
Eligibility Lymphoma, Large-Cell, Anaplastic NCT01309789
- StudyEvent: Eligibility
Description
Exclusion Criteria
Alias
- UMLS CUI
- C0680251
Description
ID.4
Data type
boolean
Description
ID.5
Data type
boolean
Description
ID.6
Data type
boolean
Description
ID.7
Data type
boolean
Description
ID.8
Data type
boolean
Description
ID.9
Data type
boolean
Similar models
Eligibility Lymphoma, Large-Cell, Anaplastic NCT01309789
- StudyEvent: Eligibility